2014 in review - IQWiG
Michael Wonder - January 2015
www.maestrodatabase.com
The German Institute
for Quality and Efficiency in Health Care (IQWiG) conducted rapid
benefit assessments on 26 new medicines/new combination products in 2014; these are
summarised below.
- Two of the 26 assessments are on-going
- Some of the new medicines have been approved by the European Commission for use by more than one patient population
- The IQWiG found two medicines to have a major additional benefit (in at least one sub-group) and another five medicines to have a significant additional benefit (in at least one sub-group). Most medicines were found to offer no additional benefit.
Rapid benefit assessments conducted by the
IQWiG for new medicines/new combination products in 2014
|
Project code
|
Medicine
|
Disease/condition
|
Sponsor
|
Level of additional
benefit (highest level in at least one sub-group)
|
|
A14-01
|
Trastuzumab emtansine (Kadcyla)
|
Breast cancer
|
Roche
|
Major
|
|
A14-02
|
Radium Ra223 dichloride (Xofigo)
|
Prostate cancer
|
Bayer
|
Major
|
|
A14-03
|
Emtricitabine with rilpivirine hydrochloride and
tenofovir disoproxil fumarate (Eviplera)
|
HIV infection
|
Gilead
|
No
|
|
A14-05
|
Sofosbuvir (Sovaldi)
|
Hepatitis C
|
Gilead
|
Non quantifiable
|
|
A14-06
|
Enzalutamide (Xtandi)
|
Prostate cancer
|
Astellas
|
Significant
|
|
A14-07
|
Dapagliflozin propanediol monohydrate
with metformin hydrochloride (Xigduo)
|
Type 2 diabetes mellitus
|
AstraZeneca
|
No
|
|
A14-08
|
Dolutegravir
sodium (Tivicay)
|
HIV
infection
|
ViiV
|
Significant
|
|
A14-12
|
Canagliflozin hemihydrate (Invokana)
|
Type 2
diabetes mellitus
|
Janssen-Cilag
|
No
|
|
A14-13
|
Insulin degludec (Tresiba)
|
Diabetes
mellitus
|
Novo Nordisk
|
No
|
|
A14-14
|
Dimethyl fumarate (Tecfidera)
|
Multiple
sclerosis
|
Biogen Idec
|
No
|
|
A14-17
|
Ruxolitinib phosphate (Jakavi)
|
Myelofibrosis
|
Novartis
|
Significant
|
|
A14-18
|
Simeprevir
sodium (Olysio)
|
Hepatitis
C
|
Janssen-Cilag
|
Significant
|
|
A14-19
|
Mirabegron (Betmiga)
|
Overactive bladder
|
Astellas
|
No
|
|
A14-22
|
Vilanterol trifenatate with umeclidinium
bromide (Anoro Ellipta)
|
Chronic obstructive pulmonary disease
|
GSK
|
No
|
|
A14-23
|
Vedolizumab (Enytvio)
|
Ulcerative colitis
|
Takeda
|
No
|
|
A14-23
|
Vedolizumab (Entyvio)
|
Crohn’s disease
|
Takeda
|
No
|
|
A14-26
|
Empagliflozin (Jardiance)
|
Type 2
diabetes mellitus
|
Boehringer Ingelheim
|
No
|
|
A14-27
|
Canagliflozin hemihydrate with metformin
hydrochloride (VokanaMet)
|
Type 2
diabetes mellitus
|
Janssen-Cilag
|
No
|
|
A14-30
|
Nalmefene hydrochloride dihydrate (Selincro)
|
Alcohol dependence
|
Lundbeck
|
No
|
|
A14-31
|
Daclatasvir dihydrochloride (Daklinza)
|
Hepatitis
C
|
BMS
|
No
|
|
A14-34
|
Abacavir sulfate with dolutegravir sodium and
lamivudine (Triumeq)
|
HIV infection
|
ViiV
|
Significant
|
|
A14-35
|
Idelalisib (Zydelig)
|
Non-Hodgkin’s lymphoma
|
Gilead
|
No
|
|
A14-35
|
Idelalisib (Zydelig)
|
Chronic lymphocytic leukaemia
|
Gilead
|
No
|
|
A14-36
|
Albiglutide (Eperzan)
|
Type 2
diabetes mellitus
|
GSK
|
Marginal
|
|
A14-37
|
Sucroferric oxyhydroxide (Velphoro)
|
Hyperphosphataemia
|
Vifor Fresenius
|
No
|
|
A14-38
|
Sipuleucel-(Provenge)
|
Prostate cancer
|
Dendreon
|
No
|
|
A14-42
|
Lurasidone hydrochloride (Latuda)
|
Schizophrenia
|
Takeda
|
On-going
|
|
A14-44
|
Ledipasvir with sofosbuvir (Harvoni)
|
Hepatitis
C
|
Gilead
|
On-going
|
©
Wonder Drug Consulting Pty Ltd, 2015.
2014 in review - Rapid benefit assessments conducted by the IQWiG
ReplyDelete